Barcelona, Spain, Saturday, October 15, 2022 – CIS Pharma will attend the 35th Annual Congress of the European Association of Nuclear Medicine in Barcelona. The team is looking forward [...]
Bubendorf, Switzerland, Tuesday, October 4, 2022 – Based on the successful developments in the radioligand program, CIS Pharma and the ETH Zürich were granted continued funding for their development collaboration. [...]
Basel, Switzerland, Wednesday, September 21, 2022 – CIS Pharma will attend the 22nd Annual Biotech in Europe Forum in Basel. Taking place during the Sachs Autumn Life Sciences Week, [...]
Bubendorf, Switzerland, Tuesday, September 18 - CIS Pharma has initiated the production of an antibody-radionuclide conjugate, ARC, based on its humanized lead anti-CD171 antibody. The ARC Lutetium-177, at a radionuclide-to-antibody [...]
Bubendorf, Switzerland, Wednesday, September 15, 2022 - CIS Pharma has initiated the production of an antibody-drug conjugate, ADC, based on its humanized lead anti-CD171 antibody. The ADC comprises monomethyl auristatin [...]
Villigen, Switzerland, Thursday, August 18, 2022 - CIS Pharma and its partner at ETH, Zürich, the division for radiopharmaceuticals, Paul Scherrer Institute, PSI, have made significant progress in their [...]
Basel, Switzerland, Monday, May 2, 2022 - CIS Pharma will attend the Swiss Biotech Day in Basel, one of the leading biotechnology conferences in Europe. The team is looking forward [...]
Bubendorf, Switzerland, Monday, March 14, 2022 - CIS Pharmas has identified two lead candidates for the development of the first nanobody polymer conjugate targeting B7H3, CD 276. Based on [...]
Bubendorf, Switzerland, Friday, December 3, 2021 – CIS Pharma and the University of Applied Sciences in Basel were granted a two-year research program by the Swiss Nanoscience Institute, SNI, to [...]
Bubendorf, Switzerland, Monday, November 22, 2021 – CIS Pharma has initiated a feasibility study to develop a novel carrier to conjugate ASO and siRNA for targeted delivery, in collaboration with [...]